arrow
M

Maria Grazia Carnevale

fondazione irccs istituto nazionale tumori
H指数:6
被引数:104

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Radiation therapy and overall survival in male breast cancer: a multicenter analysis of 302 patients

放射治疗与男性乳腺癌患者总生存期:一项对302例患者的多中心分析

2026-09-280
PRE
Postmastectomy radiation therapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer: a retrospective exploratory cohort analysis of the adjuvant lapatinib and/or trastuzumab treatment optimization (ALTTO) trial [BIG 2-06/NCCTG N063D (Alliance)]

人表皮生长因子受体2(HER2)阳性乳腺癌患者中的术后放疗:辅助拉帕替尼和/或曲妥珠胺治疗优化(ALTTO)试验(BIG 2-06/NCCTG N063D(Alliance))的回顾性探索性队列分析

2026-07-010
PRE
HER2-low breast cancer is immune-cold: insights into tumor-infiltrating immune cells and implications for immunotherapy

HER2-low乳腺癌是免疫冷型肿瘤:肿瘤浸润免疫细胞的见解及其对免疫治疗的启示

2025-12-030
OAAI
Health-related quality of life and fear of recurrence after early breast cancer treatment: results from a cross-sectional survey

健康相关生活质量及治疗后复发恐惧:一项横断面调查的结果

2025-11-130
OAAI
Advancing breast cancer therapy in the era of molecular diagnostics

分子诊断时代下乳腺癌疗法的进展

2025-05-080
OAAI
Stereotactic reirradiation with CyberknifeR for locally recurrent prostate cancer, long-term toxicity and clinical outcomes from a monocentric cohort
2023-09-201
PRE
Choline PET/CT in recurrent prostate cancer
2023-03-213
OAAI
Predictive factors for tolerance to taxane based chemotherapy in older adults affected by metastatic prostate cancer (ANCHISES-NCT05471427): A prospective observational trial including patients with metastatic hormone sensitive and castrate resistant prostate cancer treated with taxane chemotherapy
2023-01-015
PRE